Related Experiment Video

Updated: Aug 19, 2026

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
09:02

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

Published on: February 17, 2014

[Preclinical study of maxar safety]

A S Saratikov1, N S Livshits, F I Burchenkova

  • 1Pharmacology Department, Siberian Medical University, Moskovskii trakt 2, Tomsk, 634050 Russia. albert@post.tomica.ru

Eksperimental'Naia I Klinicheskaia Farmakologiia
|January 28, 2004
PubMed

Insights

Maxar, a new hepatoprotector, demonstrates low acute toxicity and no adverse effects on organs in preclinical safety evaluations. This drug is safe for long-term use, showing no mutagenic, allergenic, or reproductive toxicity.

Area of Science:

  • Pharmacology
  • Toxicology
  • Drug Safety

Context:

  • Preclinical safety evaluation of novel therapeutic agents is crucial for drug development.
  • Hepatoprotective agents are vital for managing liver diseases.

Purpose:

  • To assess the preclinical safety profile of the novel hepatoprotector, Maxar.
  • To determine the toxicological classification and potential adverse effects of Maxar.

Summary:

  • Maxar exhibits low acute toxicity, with no significant functional or structural changes observed in rats and dogs after 6-month administration at various doses.
  • The drug demonstrated no mutagenic, allergenic, immunotoxic, or adverse reproductive effects in preclinical studies.

Impact:

  • Establishes Maxar as a low-toxicity substance, supporting its progression to further clinical trials.
  • Provides critical safety data for the development of a new therapeutic option for liver conditions.

More Related Videos

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...